roxinemia,where albumin affinity forT4isabnormallyhigh (7, 8) . We furtherassessedthe interaction ofT4 and labeled analogswith circulating albumin by immunoprecipitation.
Our findings indicate that these assays largely reflect the albumin-bound T4 fraction.
Materials and Methods
We obtained sera from two subjects with hereditary analbuminemia (see acknowledgement), one of whom has never received albumin and has an undetectable concentrationofitin serum, and a sibling who has received periodic infusionsof human albumin. In the latter subject a sample had been taken on the third day after infusion of 40 g of albumin. Both subjects had high concentrations of thyroxinbinding globulin (37and 38 mgfL; normal 12-25 mg/L) with totalT4 concentrations of 136 and 160 nmollL by double- International;added mass <2% of endoge-nous albumin). Analytical recovery of albumin (mean ± SD) was similar in normal (47 ± 12%) and FDH sera (49 ± 7%), whereas precipitation of '251-labeled albumin from analbuminemic sera was almost complete (>96%). Statistical evaluation was by Student's t-test for unpaired observations. 
Results

Both
Discussion
In this study we have assessed sera with three different albumin anomalies: complete deficiency, partial deficiency, FDH (1,2) suggeststhatvariations in albumin have a marked affect on the apparent Fr4 values obtained by "unbound analog" assays. In seeking an explanation for these anomalous results, one must consider what proportion of total T4 becomes available to compete with the tracer for antibody binding (10). It is also crucial to establish which plasma proteins bind the labeled analog; such alterations will greatly alter the amount of analog tracer available to compete with Fr4.
Midgley and Wilkins (10) have suggested that the "unbound analog" Fr4 assays may allow some redistribution of unlabeled T4 from binding proteins to antibody during assay incubation.
Redistribution of only a minute fraction of albumin-bound T4 (-10 nmoIJL) could have a large influence on the Fr4 concentration (-20 pmol/L). Provided lowaffinity binding is similar in standard and test samples, the apparent Fr4 of both can be compared with use of a fairly insensitive dose-response curve (5). Our results in analbuminemia are consistent with this explanation by demonstrating spuriously low Fr4 values when albumin-associated T4 is much less in the sample than in the standard. However, it seems unlikely that redistribution of unlabeled T4 can account for the full range of anomalies in this type of assay. In our view, interaction of the labeled analog with plasma proteinbinding sites is of much greater importance.
Our immunoprecipitation studies suggest that "unbound analog" tracersbind even more stronglyto circulating albumin than does native T4, a known ligand for albumin. When T4-bindingsites on albumin are altered in affinity (as in FDH) or capacity(asin analbuminemia),there willbe major changes in the amount oflabeledanalog available to compete with available T4 forthe bindingsites of the assay antibody. When albumin binding in the sample is absent or very low, analog tracer will be more readily available in sample than in standards prepared in normal serum, giving subnormal results. The oppositeoccurs in FDH (1, 2) and with abnormal gamma-globulin binding (3, 4), where sequestration of tracer makes it less available for competition (1, 4) , giving spuriouslyhigh values.In effect, "unbound analog" measurements of Fr4 then become dependent on the intricacies ofisotope dilution as well as the principles of competitive binding.
In a previous publication, we described spuriously high FT4 valuesin FDH by the Amerlex method, and reported binding of the unidentified analog tracer by a commercial preparation of prealbumin (1). Further evaluation by polyacrylamide gel electrophoresis and autoradiography has shown that albumin contamination is responsible for this binding (Stockigt and Barlow, unpublished) , a finding consistent with the data reported here.
Our findings with qualitative or quantitative albumin anomalies should be considered with the report by Amino et al. (12) , who showed that the concentration of normal serum albumin influences the value obtained by the Amerlex FT4 assay. Besides finding a direct correlation of Fr4 with the serum albumin concentration, they also demonstrated that added normal albumin inhibited antibody binding of tracer.
The present findings suggest that hereditary analbuminemia is another situation in which "unbound analog" methods give invalid Fr4 results. Previous studies have shown falsely high estimates in FDH (1,2, 10 ) and in the presence of endogenous 'F4-binding autoantibodies (3,4) ; results were falsely low in severe nonthyroidal illness (11) and during heparin treatment (13, 14) . Despite the fact that hereditary analbuminemia is an uncommon condition,of minor diagnostic significance in relation to the thyroid, the findings reported here further demonstrate that the currently available "unbound analog" methods should not be accepted as specific for Fr4. The terminology of these assays may indeed be inappropriate.
